Kadriye Memiç Sancar1, Oğuzhan Çelik2, Cem Çil2, Osman Karaarslan3, Tolga Doğan4, Mücahit Yetim3, Ramazan Asoğlu5, Yunus Çelik6, Sedat Kalkan7, Erkan Demirci8, Emine Altuntaş9, Gökay Taylan10, Emrah Küçük11, Zafer Küçüksu12, Onur Aslan13, Murat Civan14, Özcan Başaran2, Murat Biteker2. 1. Deparment of Cardiology, Mehmet Akif Ersoy Cardiothoracic and Vascular Surgery Training and Research Hospital, İstanbul, Turkey. 2. Deparment of Cardiology, Muğla Sıtkı Koçman University Training and Research Hospital, Muğla, Turkey. 3. Deparment of Cardiology, Hitit University Erol Olçok Training and Research Hospital, Çorum, Turkey. 4. Deparment of Cardiology, Bursa İhtisas Training and Research Hospital, Bursa, Turkey. 5. Department of Cardiology, Faculty of Medicine, Adıyaman University, Adıyaman, Turkey. 6. Department of Cardiology, Kırıkkale Yüksek İhtisas Hospital, Kırıkkale, Turkey. 7. Department of Cardiology, Pendik State Hospital, İstanbul, Turkey. 8. Department of Cardiology, Kayseri Training and Research Hospital, Kayseri, Turkey. 9. Deparment of Cardiology, Şehit Prof. Dr. İlhan Varank Sancaktepe Training and Research Hospital, İstanbul, Turkey. 10. Department of Cardiology, Faculty of Medicine, Trakya University, Edirne, Turkey. 11. Department of Cardiology, Kızıltepe State Hospital, Mardin, Turkey. 12. Department of Cardiology, Faculty of Medicine, Erzincan University, Erzincan, Turkey. 13. Department of Cardiology, Tarsus State Hospital, Mersin, Turkey. 14. Department of Cardiology, Nişantaşı University Bahçelievler Vital Hospital, İstanbul, Turkey.
Abstract
BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension. RESULTS: Aspirin use for primary prevention was higher in patients with hypertension compared to patients without hypertension [328 (21.3%); 1046 (30.2%); P < .001]. Treatment with a dose of 150 mg aspirin (n=172, 5%) was mostly preferred by internists for hypertensive patients (n =226, 6.5%); however, a daily dose of 80-100 mg aspirin therapy (n=1457, 94.6%) was mostly prescribed by cardiologists (n=1347, 87.5%) for patients without hypertension. CONCLUSION: Aspirin was found to be used commonly among patients with hypertension for primary prevention despite the current European Society of Cardiology Arterial Hypertension Guideline not recommending aspirin for primary prevention in patients with hypertension.
BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension. RESULTS: Aspirin use for primary prevention was higher in patients with hypertension compared to patients without hypertension [328 (21.3%); 1046 (30.2%); P < .001]. Treatment with a dose of 150 mg aspirin (n=172, 5%) was mostly preferred by internists for hypertensive patients (n =226, 6.5%); however, a daily dose of 80-100 mg aspirin therapy (n=1457, 94.6%) was mostly prescribed by cardiologists (n=1347, 87.5%) for patients without hypertension. CONCLUSION: Aspirin was found to be used commonly among patients with hypertension for primary prevention despite the current European Society of Cardiology Arterial Hypertension Guideline not recommending aspirin for primary prevention in patients with hypertension.
Authors: Jeffrey S Berger; Maria C Roncaglioni; Fausto Avanzini; Ierta Pangrazzi; Gianni Tognoni; David L Brown Journal: JAMA Date: 2006-01-18 Impact factor: 56.272
Authors: Bryan Williams; Giuseppe Mancia; Wilko Spiering; Enrico Agabiti Rosei; Michel Azizi; Michel Burnier; Denis L Clement; Antonio Coca; Giovanni de Simone; Anna Dominiczak; Thomas Kahan; Felix Mahfoud; Josep Redon; Luis Ruilope; Alberto Zanchetti; Mary Kerins; Sverre E Kjeldsen; Reinhold Kreutz; Stephane Laurent; Gregory Y H Lip; Richard McManus; Krzysztof Narkiewicz; Frank Ruschitzka; Roland E Schmieder; Evgeny Shlyakhto; Costas Tsioufis; Victor Aboyans; Ileana Desormais Journal: Eur Heart J Date: 2018-09-01 Impact factor: 29.983
Authors: James F Meschia; Cheryl Bushnell; Bernadette Boden-Albala; Lynne T Braun; Dawn M Bravata; Seemant Chaturvedi; Mark A Creager; Robert H Eckel; Mitchell S V Elkind; Myriam Fornage; Larry B Goldstein; Steven M Greenberg; Susanna E Horvath; Costantino Iadecola; Edward C Jauch; Wesley S Moore; John A Wilson Journal: Stroke Date: 2014-10-28 Impact factor: 7.914
Authors: J A Cairns; M Gent; J Singer; K J Finnie; G M Froggatt; D A Holder; G Jablonsky; W J Kostuk; L J Melendez; M G Myers Journal: N Engl J Med Date: 1985-11-28 Impact factor: 91.245
Authors: Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redón; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stéphane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad Journal: J Hypertens Date: 2013-07 Impact factor: 4.844